Kenneth G. Romanzi
Known title: Chief Executive OfficerCIK: 0001724435
Associated companies
Transaction History
| NATR | ▲ Buy | Grant | 33,753 | $0 | 5/15/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 13,118 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 5,753 | $149K | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Other | 29,928 | — | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Grant | 29,928 | $750K | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Grant | 102,881 | $1.5M | 11/4/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.